Abstract

Case Report

Allogeneic hematopoietic cell transplantation to treat two synchronous hematologic malignancies

Enrico Santinelli*, Raffaella Cerretti, Gottardo De Angelis, Benedetta Mariotti, Giulia Ciangola, Camilla Page, Elisa Lindfors Rossi, Gianmario Pasqualone and William Arcese

Published: 10 June, 2022 | Volume 6 - Issue 1 | Pages: 005-000

Allogeneic hematopoietic cell transplantation often represents the only solution for several poor-prognosis hematologic malignancies. The curative strategy for patients with synchronous hematologic disorders is always difficult and, in most cases, ineffective. Herein, we report an unusual case of synchronous hematologic disorders successfully treated with an “ad-hoc” conditioning regimen followed by allogeneic hematopoietic cell transplantation.

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001025 Cite this Article Read Full Article PDF

Keywords:

Allogeneic hematopoietic cell transplantation; Synchronous hematologic malignancies; Conditioning regimen; Graft versus tumor

References

  1. Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020 Nov;95(11):1399-1420. doi: 10.1002/ajh.25950. PMID: 32744763.
  2. Khong T, Sharkey J, Spencer A. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica. 2008 Jun;93(6):860-9. doi: 10.3324/haematol.12261. Epub 2008 Apr 28. PMID: 18443271.
  3. Abatay-Sel F, Savran-Oguz F, Kalayoglu-Besisik S, Mastanzade M, Duvarci-Ogret Y, Yonal-Hindilerden I, Aydin F. Short Tandem Repeat-Polymerase Chain Reaction (STR-PCR) with Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) Method Using for Chimerism Analysis. Clin Lab. 2019 Sep 1;65(9). doi: 10.7754/Clin.Lab.2019.190221. PMID: 31532093.
  4. Mufti GJ, Hamblin TJ, Clein GP, Race C. Coexistent myelodysplasia and plasma cell neoplasia. Br J Haematol. 1983 May;54(1):91-6. doi: 10.1111/j.1365-2141.1983.tb02070.x. PMID: 6849839.
  5. Florensa L, Vallespí T, Woessner S, Domingo A, Crespo N, Rozman M, Aguilar JL, Irriguible D, Zarco A, Millá F, Feliu E. Incidence and characteristics of lymphoid malignancies in untreated myelodysplastic syndromes. Leuk Lymphoma. 1996 Nov;23(5-6):609-12. doi: 10.3109/10428199609054871. PMID: 9031093.
  6. Zimmerman Z, Scott BL, Gopal AK, Sandmaier BM, Maloney DG, Deeg HJ. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy. Bone Marrow Transplant. 2012 Jun;47(6):804-9. doi: 10.1038/bmt.2011.180. Epub 2011 Sep 12. PMID: 21909142; PMCID: PMC3237793.
  7. Ortega M, Mallo M, Solé F, Sánchez-Morata C, López-Andreoni L, Martínez-Morgado N, Gironella M, Valcárcel D, Vallespí T. 5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide. Leuk Res. 2013 Oct;37(10):1248-50. doi: 10.1016/j.leukres.2013.06.021. Epub 2013 Jul 26. PMID: 23891188.
  8. Nishihori T, Komrokji R, Shain K, Anasetti C. Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome. Bone Marrow Transplant. 2015 Feb;50(2):296-7. doi: 10.1038/bmt.2014.233. Epub 2014 Oct 20. PMID: 25330222.
  9. Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant. 1998 Nov;22(9):835-43. doi: 10.1038/sj.bmt.1701459. PMID: 9827810.
  10. Gröger M, Gagelmann N, Wolschke C, von Pein UM, Klyuchnikov E, Christopeit M, Zander A, Ayuk F, Kröger N. Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 Jul;24(7):1399-1405. doi: 10.1016/j.bbmt.2018.04.018. Epub 2018 Apr 21. PMID: 29684563.
  11. Frey NV, Porter DL. Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol. 2008 Jun;21(2):205-22. doi: 10.1016/j.beha.2008.02.007. PMID: 18503987; PMCID: PMC2504712.
  12. Scarisbrick JJ, Dignan FL, Tulpule S, Gupta ED, Kolade S, Shaw B, Evison F, Shah G, Tholouli E, Mufti G, Pagliuca A, Malladi R, Raj K. A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transplant. 2015 Jan;50(1):62-7. doi: 10.1038/bmt.2014.227. Epub 2014 Oct 13. PMID: 25310308.
  13. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22. PMID: 20410922; PMCID: PMC7020664.

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Similar Articles

  • Allogeneic hematopoietic cell transplantation to treat two synchronous hematologic malignancies
    Enrico Santinelli*, Raffaella Cerretti, Gottardo De Angelis, Benedetta Mariotti, Giulia Ciangola, Camilla Page, Elisa Lindfors Rossi, Gianmario Pasqualone and William Arcese Enrico Santinelli*,Raffaella Cerretti,Gottardo De Angelis,Benedetta Mariotti,Giulia Ciangola,Camilla Page,Elisa Lindfors Rossi,Gianmario Pasqualone,William Arcese. Allogeneic hematopoietic cell transplantation to treat two synchronous hematologic malignancies. . 2022 doi: 10.29328/journal.jsctt.1001025; 6: 005-000

Recently Viewed

Read More

Most Viewed

Read More